Lung Cancer Therapy Annual 7

Oncology research and practice in lung cancer continues to develop rapidly. This latest edition of Lung Cancer Therapy Annual briefs the oncology community with a review of the recent literature, emphasizing the therapeutic aspects.

It offers an update of the impact that this information will have on the day-to-day management of the lung cancer patient.

New to the Seventh Edition:

• An update of the impact of recent developments will have on day-to-day management of lung cancer patients
• Four new chapters on the treatment of non-small cell lung cancer (NSCLC)
• A new chapter on thymoma

Additional topics include:

• Oncogenic driver mutations
• First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
• Second line therapy of non-small cell lung cancer
• Adjunct and neoadjunct therapy of non-small cell lung cancer
• Advances in surgery of lung cancer; advances in radiotherapy of lung cancer
• Mesothelioma
• Thymic tumors

• 1. Epidemiology
• 2. Prevention, early detection, and screening
• 3. Staging
• 4. Histopathology and molecular pathology
• 5. Oncogenic driver mutations
• 6. First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
• 7. First line therapy of advanced non-small cell lung cancer with activating EGFR mutation
• 8. Second line therapy of non-small cell lung cancer
• 9. Adjuvant and neoadjuvant therapy of non-small cell lung cancer
• 10. Advances in surgery of lung cancer
• 11. Advances in radiotherapy of lung cancer
• 12. Small cell lung cancer
• 13. Mesothelioma
• 14. Thymoma